Compare TransMedics Group Inc (TMDX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Workiva Inc — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Workiva Inc trades at $73.27 (market cap $4.01B). The key difference: Workiva Inc is the larger of the two by market cap, and Workiva Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Workiva Inc for 21 Days on average.
| TMDX | WK | |
|---|---|---|
Market Cap | $2.74B | $4.01B |
Volume | 949,331 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $150.42 | $93.31 |
52-Week Low | $61.99 | $44.31 |
Typical Hold Time | 24 Days | 21 Days |
Enterprise Value | $3.13B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Workiva (WK) trades at $73.20, up 2.33% with bullish technical indicators and strong analyst support. The company shows improving fundamentals with revenue growth from $885M to $966M and a shift from a $26M loss to $47M profit in 2026. Recent product innovations in AI and regulatory platforms highlight business momentum, supported by consistent earnings beats in recent quarters.
Outlook remains positive with 89% analyst buy ratings and $86 consensus target offering 17% upside. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in regulatory technology. The stock's technical strength and fundamental improvement suggest continued growth potential, though investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
